| Sunnyside Home Health | |
| 812 Miller Avenue Ste A, Sunnyside, Washington 98944 | |
| (509) 837-1567 | |
| Name | Sunnyside Home Health |
|---|---|
| Location | 812 Miller Avenue Ste A, Sunnyside, Washington |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 507126 |
| Ownership Type | Voluntary Non-profit - Private |
| Service Area Zip Codes | 98903, 98930, 98932, 98935, 98938, 98944, 98948, 98951, 98952, 98953, 99350 |
| NPI Number | 1669918405 |
| Organization Name | SUNNYSIDE HOME HEALTH |
| Address | 812 Miller Ave, Suite A, Sunnyside, WA 98944 |
| Phone Number | 509-837-1567 |
News Archive
Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.
The Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, released a new white paper, "The State of Biosimilars Policy." The paper is released in conjunction with a congressional briefing on Capitol Hill where experts will discuss the current biosimilars policy framework and its impact on prescribing, reimbursement and use.
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced it will launch two new Digital X-Ray Flat Panel Detectors (FPDs) for Non Destructive Testing (NDT) applications at the ASNT Fall Conference and Quality Testing Show in Houston, Texas, from November 15-17 at booth 725.
The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.
› Verified 8 days ago
| Quality Rating: |
News Archive
Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.
The Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, released a new white paper, "The State of Biosimilars Policy." The paper is released in conjunction with a congressional briefing on Capitol Hill where experts will discuss the current biosimilars policy framework and its impact on prescribing, reimbursement and use.
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced it will launch two new Digital X-Ray Flat Panel Detectors (FPDs) for Non Destructive Testing (NDT) applications at the ASNT Fall Conference and Quality Testing Show in Houston, Texas, from November 15-17 at booth 725.
The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 98.1 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 100 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 81.4 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 87.7 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98.8 | 96.4 |
News Archive
Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.
The Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, released a new white paper, "The State of Biosimilars Policy." The paper is released in conjunction with a congressional briefing on Capitol Hill where experts will discuss the current biosimilars policy framework and its impact on prescribing, reimbursement and use.
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced it will launch two new Digital X-Ray Flat Panel Detectors (FPDs) for Non Destructive Testing (NDT) applications at the ASNT Fall Conference and Quality Testing Show in Houston, Texas, from November 15-17 at booth 725.
The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 85.1 | 79.6 |
| How often patients got better at getting in and out of bed | 82.5 | 81.1 |
| How often patients got better at bathing | 91.7 | 82.3 |
| How often patients’ breathing improved | 86.9 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 90 | 75 |
| How often home health patients had to be admitted to the hospital | 16 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 23.2 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 96.2 | 94 |
News Archive
Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.
The Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, released a new white paper, "The State of Biosimilars Policy." The paper is released in conjunction with a congressional briefing on Capitol Hill where experts will discuss the current biosimilars policy framework and its impact on prescribing, reimbursement and use.
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced it will launch two new Digital X-Ray Flat Panel Detectors (FPDs) for Non Destructive Testing (NDT) applications at the ASNT Fall Conference and Quality Testing Show in Houston, Texas, from November 15-17 at booth 725.
The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.
› Verified 8 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | Not Available |
| Health team communicated well with them | Not Available |
| Health team discussed medicines, pain, and home safety | Not Available |
| How patients rated overall care from agency | Not Available |
News Archive
Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.
The Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, released a new white paper, "The State of Biosimilars Policy." The paper is released in conjunction with a congressional briefing on Capitol Hill where experts will discuss the current biosimilars policy framework and its impact on prescribing, reimbursement and use.
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced it will launch two new Digital X-Ray Flat Panel Detectors (FPDs) for Non Destructive Testing (NDT) applications at the ASNT Fall Conference and Quality Testing Show in Houston, Texas, from November 15-17 at booth 725.
The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.
› Verified 8 days ago
The patient survey data of Sunnyside Home Health is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 87 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 82 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 91 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 82 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 77 | 78 |
News Archive
Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.
The Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, released a new white paper, "The State of Biosimilars Policy." The paper is released in conjunction with a congressional briefing on Capitol Hill where experts will discuss the current biosimilars policy framework and its impact on prescribing, reimbursement and use.
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced it will launch two new Digital X-Ray Flat Panel Detectors (FPDs) for Non Destructive Testing (NDT) applications at the ASNT Fall Conference and Quality Testing Show in Houston, Texas, from November 15-17 at booth 725.
The University of Alaska Fairbanks will study how the genetics and diet of Yup'ik Eskimos affect the blood-thinning properties of a common drug used by heart and stroke patients.
› Verified 8 days ago
Sunnyside Home Health Location: 812 Miller Avenue Ste A, Sunnyside, Washington 98944 Ratings: Phone: (509) 837-1567 |